Barcode Nanotech
Target-specific nanoparticles for next generation RNA therapies
Company Overview
Snapshot
Founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah, Barcode Nanotech operates with 1–10 employees. The company has raised $7.6 million across five funding rounds from four investors. In August 2022, NGT HealthCare II participated in a funding round.
Business overview
Barcode Nanotech specializes in developing targeted delivery vehicles for RNA/DNA therapeutics, addressing the critical need for precise and safe delivery to target organs and cells. The company's core technology involves proprietary Lipid Nanoparticles (LNPs) designed to selectively reach target cells and tissues while protecting RNA molecules from degradation. Barcode Nanotech leverages an AI-based platform for designing these LNPs and a high-throughput in vivo screening platform for rapid testing and optimization. It serves markets focused on selective indications such as hard-to-treat cancers, metabolic diseases, and fibrosis, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In July 2026, Barcode Nanotech collaborated with Galmed to develop a novel LNP cardiac-targeted formulation of Galmed's SCD1 inhibitor, Aramchol. This partnership signals Barcode Nanotech's capability in applying its proprietary LNP technology to specific therapeutic areas, demonstrating its potential for strategic collaborations within the pharmaceutical industry and validating its platform for targeted drug delivery.
Company Intelligence Q&A
- What is Barcode Nanotech's primary focus?
- Barcode Nanotech focuses on developing targeted delivery vehicles, specifically proprietary Lipid Nanoparticles (LNPs), for next-generation RNA/DNA therapies to ensure precise and safe delivery to target organs and cells.
- When was Barcode Nanotech founded?
- Barcode Nanotech was founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah.
- Which investor participated in a funding round in August 2022?
- In August 2022, NGT HealthCare II participated in a funding round for Barcode Nanotech.
- What significant collaboration did Barcode Nanotech announce in July 2026?
- In July 2026, Barcode Nanotech announced a collaboration with Galmed, resulting in the breakthrough development of a novel LNP cardiac-targeted formulation of Galmed's SCD1 inhibitor, Aramchol.
- What was the nature of the funding round in June 2017?
- In June 2017, Barcode Nanotech received funding from NGT3 and the Israel Innovation Authority in a Seed round.